LENZ LENZ Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: LENZ

Price (delayed)

$3.76

Market cap

$118.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.13

Enterprise value

$94.05M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 20

Graphite Bio, Inc. has historically been a clinical-stage, next-generation gene editing company. In February 2023, Graphite Bio announced its decision to discontinue the development of nulabeglogene autogedtemcel ("nula-cel"), Graphite Bio’s ...

Highlights
LENZ Therapeutics's debt has shrunk by 79% YoY and by 49% QoQ
The revenue is up by 2.3% since the previous quarter
LENZ Therapeutics's quick ratio has decreased by 36% YoY but it has increased by 28% from the previous quarter
The equity has declined by 11% since the previous quarter but it is up by 6% year-on-year
The company's net income has shrunk by 140% YoY and by 16% QoQ
The EPS has plunged by 123% YoY and by 13% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of LENZ

LENZ stock price

How has the LENZ Therapeutics stock price performed over time
Intraday
-8.96%
1 week
-9.18%
1 month
-19.66%
1 year
-90.72%
YTD
-76.5%
QTD
-33.8%

Financial performance

How have LENZ Therapeutics's revenue and profit performed over time
Revenue
$21.48M
Gross profit
$19.7M
Operating income
-$135.66M
Net income
-$126M
Gross margin
91.7%
Net margin
-586.7%
The company's net income has shrunk by 140% YoY and by 16% QoQ
LENZ's operating income has dropped by 119% year-on-year and by 15% since the previous quarter
LENZ's operating margin is up by 49% year-on-year but it is down by 12% since the previous quarter
LENZ Therapeutics's net margin has increased by 44% YoY but it has decreased by 13% QoQ

Price vs fundamentals

How does LENZ's price correlate with its fundamentals

Growth

What is LENZ Therapeutics's growth rate over time

Valuation

What is LENZ Therapeutics stock price valuation
P/E
N/A
P/B
0.54
P/S
5.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.38
The EPS has plunged by 123% YoY and by 13% from the previous quarter
The stock's price to book (P/B) is 77% less than its last 4 quarters average of 2.6 and 71% less than its 5-year quarterly average of 2.0
The equity has declined by 11% since the previous quarter but it is up by 6% year-on-year
The stock's price to sales (P/S) is 80% less than its last 4 quarters average of 30.5
The revenue is up by 2.3% since the previous quarter

Efficiency

How efficient is LENZ Therapeutics business performance
LENZ Therapeutics's ROE has plunged by 109% YoY and by 14% from the previous quarter
The return on invested capital has dropped by 101% year-on-year and by 13% since the previous quarter
LENZ's return on assets has dropped by 101% year-on-year and by 13% since the previous quarter
The ROS has grown by 43% YoY but it has contracted by 14% from the previous quarter

Dividends

What is LENZ's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did LENZ Therapeutics financials performed over time
LENZ's total liabilities has soared by 58% year-on-year but it is down by 33% since the previous quarter
LENZ Therapeutics's quick ratio has decreased by 36% YoY but it has increased by 28% from the previous quarter
LENZ Therapeutics's debt is 100% lower than its equity
LENZ Therapeutics's debt has shrunk by 79% YoY and by 49% QoQ
The equity has declined by 11% since the previous quarter but it is up by 6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.